Company: REVB
Filing Date: 2025-03-17
Form Type: 8-K
Source: 0000950170-25-040294
Chunk: 0

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On March 17, 2025, Revelation Biosciences, Inc. (the “ Company”) issued a press release titled “ Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells” announcing preclinical results demonstrating that priming human peripheral blood mononuclear cells (PBMSs) with its drug candidate Gemini significantly attenuated inflammatory responses to HMGB-1 (a tissue injury marker) and LPS (a bacterial infection marker). Additionally, the Company made an updated corporate presentation available to the public, the corporate presentation can be found on the Company’s website. A copy of the press release and presentation are attached to this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively and are incorporated herein by reference.

The information in Item 8.01 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Item 9.01 Financial Statements and Exhibits.